Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

DEX-2-TKA-DEXamethasone twice for pain treatment after Total Knee Arthroplasty: A protocol for a randomized, blinded, three-group multicentre clinical trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. APACHE II score validation in emergency abdominal surgery. A post hoc analysis of the InCare trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Depth to the airway lumen at the level of the cricothyroid membrane measured by ultrasound

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effects of magnesium, phosphate and zinc supplementation in ICU patients-Protocol for a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  • Kasper S Gasbjerg
  • Daniel Hägi-Pedersen
  • Troels H Lunn
  • Janus C Jakobsen
  • Søren Overgaard
  • Niels A Pedersen
  • Jens Bagger
  • Peter Lindholm
  • Stig Brorson
  • Henrik M Schrøder
  • Kasper H Thybo
  • Ole Mathiesen
Vis graf over relationer

BACKGROUND: Multimodal analgesia is considered the leading principle for post-operative pain treatment, but no gold standard after total knee arthroplasty (TKA) exists.

AIM: To investigate the beneficial and harmful effects of one or two doses of 24 mg intravenous dexamethasone (DXM) as part of a multimodal analgesic regimen (paracetamol, NSAID and perioperative local infiltration analgesia) after TKA. We hypothesize that addition of DXM will reduce post-operative opioid consumption.

METHODS: DEXamethasone twice for pain treatment after TKA is a randomized, blinded, three-group multicentre clinical trial. Participants will be randomized to one of three groups: placebo, single dose of DXM or two consecutive doses of DXM. Participants, treatment providers and investigators will be blinded to the allocated intervention. The primary outcome is total opioid consumption (units of morphine equivalents) 0-48 hours post-operatively.

INCLUSION CRITERIA: unilateral, primary TKA; age ≥18 years; American Society of Anesthesiologists-Score 1-3; Body Mass Index ≥18 and ≤40; for women-not pregnant; and written informed consent.

EXCLUSION CRITERIA: allergy or contraindications against trial medication; daily use of high dose opioid and/or use of methadone/transdermal opioids; daily use of systemic glucocorticoids; dysregulated diabetes; and patients suffering from alcohol and/or drug abuse. Four-hundred-and-eighty-six eligible participants are needed to detect or discard a difference of 10 mg morphine equivalents 0-48 hours post-operatively maintaining a familywise error rate of 0.05 and a power of 90% for the three possible pairwise comparisons.

DISCUSSION: Recruiting is planned to commence September 2018 and expected to finish March 2020.

TRIAL REGISTRATION: EudraCT: 2018-001099-39 (08/06-18); ClinicalTrials.gov: NCT03506789 (24/04-2019). Editorial Comment This is the protocol for the largest randomized clinical trial investigating the effect of one or two doses of dexamethasones on pain treatment after total knee arthroplasty. Due to the pragmatic and rigerous design this study will deliver results of high quality and external validity.

OriginalsprogEngelsk
TidsskriftActa Anaesthesiologica Scandinavica
Vol/bind64
Udgave nummer2
Sider (fra-til)267-275
Antal sider9
ISSN0001-5172
DOI
StatusUdgivet - feb. 2020

Bibliografisk note

© 2019 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

ID: 58951792